三叶草生物制药有限公司（02197）于2026年1月7日发布2025年12月股份变动月报。公告显示，截至2025年12月31日，公司注册股本维持为2,000,000,000股普通股，面值每股USD 0.0001，总额USD 200,000；本月无任何新增发行或股本变动。
公司已发行股本仍为1,297,836,552股普通股，库存股数量为0，显示报告期内并无购回、注销或库藏活动。期权方面，首次公开发售前购股权计划维持1,664,317份期权，首次公开发售后购股权计划维持32,698,855份期权，报告期内未产生行使、授出或失效变动。
整体而言，公司于2025年12月的股份数量和结构均未发生变化，截至月末股本保持稳定。公司声明，其已遵守香港联交所《上市规则》及相关法律法规。本次报告由公司董事梁朋签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.